TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A randomized phase I/II trial found that a bimatoprost-releasing intraocular lens lowered eye pressure over 12 months by an amount noninferior to a standard lens used with timolol drops. Vision was preserved and safety outcomes were similar across groups; follow-up is continuing, and two phase III trials have begun.
A bimatoprost-releasing intraocular lens lowered eye pressure by a similar amount to standard treatment with a lens implant and timolol eye drops in a 12-month randomized trial of patients with cataracts and glaucoma or ocular hypertension, researchers reported at the American Academy of Ophthalmology meeting in New Orleans. The device met the study’s noninferiority criteria against the eye-drop regimen; the results are early and do not establish long-term effectiveness.
The phase I/II multicenter trial randomized 104 patients in a 2:1:1 allocation to one of two drug-releasing lens doses, or to a standard intraocular lens plus timolol drops twice daily. Patients in the lens groups also used artificial tears twice daily. The study’s primary endpoint was reduction in intraocular pressure (IOP), measured at matched times of 8 a.m. and 10 a.m. The median participant age was 70; 85% had open-angle glaucoma and the remainder had ocular hypertension.
At 8 a.m., average IOP fell by 8.85 mm Hg in the higher-dose lens group, 11.36 mm Hg in the lower-dose group and 9.14 mm Hg in the control group. At 10 a.m., average reductions were 8 to 9 mm Hg across all three groups. Percentage reductions were 34.44% to 42.16% at 8 a.m. and 33.30% to 39.93% at 10 a.m.; the differences were not statistically significant, and both lens doses met the trial’s noninferiority criteria compared with control.
At 12 months, almost all participants remained free of additional glaucoma medication: all control patients, 98.0% of the higher-dose group and 95.7% of the lower-dose group. All participants achieved at least 20/32 best-corrected distance vision. Adverse events occurred at similar rates among the groups; the report said no participant experienced a serious adverse event or needed a secondary operation or lens removal.
A Drug Delivery Alternative During Cataract Surgery
The lens is designed to combine cataract-related vision correction with sustained delivery of bimatoprost, a glaucoma medication, in one surgical intervention. If later trials support these results, the approach could offer some patients an alternative to relying on regular pressure-lowering drops after surgery. The potential relevance is adherence: trial presenter Jeffrey Kammer said daily eye-drop use can be difficult for patients, and cited reported nonadherence rates of 30% to 50%, with some reports as high as 80%.
Those figures describe the adherence problem cited by the presenter; they do not show that this lens improves adherence or prevents glaucoma progression. The present trial compared pressure reduction and other clinical outcomes over 12 months. Its findings do not yet establish whether the lens changes long-term vision outcomes, reduces treatment burden in routine care, or is preferable for particular patients.
bimatoprost releasing intraocular lens
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Lens Releases Bimatoprost
The BIM-IOL has two drug pads, each containing 39 micrograms of bimatoprost, and is designed to release the medication continuously over three years. Kammer presented the 12-month results at the American Academy of Ophthalmology meeting. He said the device is implanted in the capsular bag during cataract surgery and is intended to preserve the eye’s angle, leaving minimally invasive glaucoma surgery as a possible future option if needed.
An earlier first-in-human study, reported the year before, included 21 evaluable patients. According to the report, their IOP fell by an average of 37%; one patient required additional glaucoma medication during three years of follow-up, and all achieved 20/30 vision. No product-related adverse events were reported in that small study. Its size and early-stage design mean those results provide preliminary context, not a substitute for larger controlled trials.
“The BIM-IOL system represents a new direction in drug delivery.”
— Jeffrey Kammer, MD, Vanderbilt University Medical Center, presenting the results
Long-Term Benefit Remains Unproven
The reported comparison covers 12 months, while follow-up is planned to continue for three years. The results do not yet show whether pressure reduction will persist, how the device performs over longer periods, or whether it reduces glaucoma progression or the need for later treatment. The source report also does not provide detailed event rates for individual adverse effects or enough information to compare outcomes for specific patient subgroups.
The trial found similar safety profiles during the reported period, but that does not establish that the device has no risks. Nor does the report establish that patients using the lens can avoid all glaucoma medication: a small proportion of lens recipients had already needed additional treatment by month 12. Longer follow-up and phase III data are needed to clarify those questions.
Phase III Trials Will Extend Testing
Kammer said two phase III trials have begun. The planned three-year follow-up of the phase I/II study will also provide information beyond the 12-month results now reported. Future results will help show whether the pressure-lowering effect and vision outcomes persist, how often patients need additional medication, and what safety issues may emerge over time. The report did not give enrollment targets, completion dates or a timetable for publication of the phase III findings.
Key Questions
What did the trial find?
At 12 months, both doses of the bimatoprost-releasing lens met the study’s noninferiority criteria versus a standard lens with timolol drops for reducing eye pressure. The percentage decreases did not differ significantly among the three groups.
Who took part in the study?
The analysis included 104 randomized patients with cataracts and glaucoma or ocular hypertension. Their median age was 70, and 85% had open-angle glaucoma.
Did the lens preserve vision?
All participants achieved at least 20/32 best-corrected distance vision at the reported assessment. The study also reported similar adverse-event proportions across groups, with no serious adverse events reported.
Does the lens eliminate the need for glaucoma drops?
The results do not show that it eliminates medication for everyone. By 12 months, 98.0% of the higher-dose group and 95.7% of the lower-dose group had not needed additional glaucoma medication; all control patients remained free of additional medication.
What happens next?
Follow-up is planned for three years, and the presenter said two phase III trials have begun. Their results are needed to assess longer-term effectiveness and safety.
Source: rss
Columbus Day / Indigenous Peoples' Day Picks
long weekend sales
As an affiliate, we earn on qualifying purchases.
